Trial Profile
A multicenter, randomized, open-label, parallel-group, phase 3 trial of subcutaneous azacitidine plus best supportive care versus conventional care regimens plus best supportive care for the treatment of myelodysplastic syndromes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Cytarabine; Daunorubicin; Idarubicin; Mitoxantrone
- Indications Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation; Pharmion Corporation
- 03 Dec 2021 Results of a network meta-analysis of data from VIALE-A, VIALE-C, AZA-001, AZA-AML-001, and DACO-016 studies presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 24 May 2017 Results developing cost-effectiveness survival analysis model using patient data of this study presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 08 Dec 2015 Results (safety analysis of AZA-AML-001 (n = 236) and AZA-001 (n = 175) studies) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology